Bioregulatory therapy in the treatment of acute and chronic rhinitis
S.A. Karpishchenko, O.M. Kolesnikova

Pavlov First St. Petersburg State Medical University, Saint Petersburg

Acute respiratory viral infections (ARVI) — the common pathology that occurs regardless of age, place of residence and social status of a person. The entrance gates of the body for the virus — an upper respiratory tract, most often through the nasal mucous membranes. With long-term acute inflammation of the nasal mucous membranes, complications may develop with the formation of chronic processes: irreversible changes of the paranasal sinuses and nasal mucous membranes develop in addition to bacterial inflammation and persistence of mucosal edema. Therefore, it is advisable to carry out not only symptomatic, but also anti-inflammatory and antimicrobial therapy of rhinitis in a timely manner. The article reviewed the studies evaluating the effectiveness of the components of the nasal spray Euphorbium compositum Nasentropfen S^®. Due to the wide range of a complex effect, this drug can be recommended for the treatment of various forms of rhinitis. Euphorbium compositum Nasentropfen S^® has antiedematous, antiviral, immunomodulatory and antibacterial action, suitable for irrigation therapy during the epidemiological risk of ARVI. To achieve the best result, the drug should be used at the first signs of incipient ARVI.ё

Key words: rhinitis, antiviral effect, symptomatic therapy, bioregulatory medicine, Euphorbium compositum Nasentropfen S^®.
For citation: Karpishchenko S.A., Kolesnikova O.M. Bioregulatory therapy in the treatment of acute and chronic rhinitis // RMJ. 2018. № 10(II). P. 75–78.